Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Motor Fluctuations Clear all
Completed Phase 3 Interventional Results available

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

NCT00357994
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa carbidopa intestinal gel (LCIG), Placebo gel, Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes

NCT01777555
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301, Placebo
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 80 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Little Rock, Arkansas • Boca Raton, Florida • Port Charlotte, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 3 Interventional

Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.

NCT00203177
View directory record Official record
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate, rasagiline mesylate 1.0 mg
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
30 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
7
States / cities
Fresno, California • Atlanta, Georgia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Sep 24, 2026, 5:34 AM EDT
Completed No phase listed Observational

Opicapone Treatment Initiation Open-Label Study

NCT04787965
View directory record Official record
Conditions
Parkinson Disease
Interventions
Opicapone
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Los Gatos, California • Memphis, Tennessee • Christiansburg, Virginia + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2022 · Synced Sep 24, 2026, 5:34 AM EDT
Recruiting Not applicable Interventional

Optimizing Adaptive DBS for Parkinson's Disease

NCT07798271
View directory record Official record
Conditions
PARKINSON DISEASE (Disorder)
Interventions
aDBS-Extended (Medtronic Percept™), aDBS-Standard (Medtronic Percept™), Continuous DBS (cDBS) - Active Control (Medtronic Percept™)
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

NCT00660387
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa carbidopa intestinal gel (LCIG), Placebo Gel, Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • Fountain Valley, California • Oceanside, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Sep 24, 2026, 5:34 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease.

NCT03051607
View directory record Official record
Conditions
Idiopathic Parkinson Disease
Interventions
Tozadenant
Drug
Lead sponsor
Biotie Therapies Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease

NCT02542696
View directory record Official record
Conditions
Parkinson Disease
Interventions
APL-130277
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 24, 2026, 5:34 AM EDT
Withdrawn Phase 4 Interventional

Keppra IV for the Treatment of Motor Fluctuations in Parkinson's Disease

NCT00584025
View directory record Official record
Conditions
Parkinson's Disease
Interventions
levetiracetam, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
30 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Sep 24, 2026, 5:34 AM EDT
Recruiting Phase 4 Interventional

BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease

NCT07138560
View directory record Official record
Conditions
Parkinson Disease
Interventions
CREXONT ER
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Terminated Phase 2 Interventional

DNS-7801 vs. Placebo in Parkinson's Disease

NCT03306329
View directory record Official record
Conditions
Parkinson's Disease
Interventions
DNS-7801 (low-dose), DNS-7801 (high dose), Placebo
Drug
Lead sponsor
Dart NeuroScience, LLC
Industry
Eligibility
30 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
9
States / cities
Long Beach, California • Pasadena, California • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Sep 24, 2026, 5:34 AM EDT
Active, not recruiting Phase 3 Interventional

To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications

NCT06553027
View directory record Official record
Conditions
Parkinson Disease
Interventions
CVN424 75 mg, CVN424 150 mg, Placebo
Drug
Lead sponsor
Cerevance
Industry
Eligibility
30 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aliso Viejo, California + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 3 Interventional

An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.

NCT00407095
View directory record Official record
Conditions
Advanced Stage Parkinson's Disease
Interventions
Pardoprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
14
States / cities
La Jolla, California • San Francisco, California • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2010 · Synced Sep 24, 2026, 5:34 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

NCT07432958
View directory record Official record
Conditions
Parkinson Disease
Interventions
AP-472, Placebo
Drug · Other
Lead sponsor
Appello Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Little Rock, Arkansas • Carlsbad, California • Los Alamitos, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

NCT02242487
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 86 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
55
States / cities
Scottsdale, Arizona • Fresno, California • Fullerton, California + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations

NCT03608371
View directory record Official record
Conditions
Parkinson Disease, Motor Disorder
Interventions
BTRX-246040, Placebo
Drug
Lead sponsor
BlackThorn Therapeutics, Inc.
Industry
Eligibility
30 Years to 76 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
4
States / cities
Hallandale, Florida • Farmington Hills, Michigan • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Randomized Safety Study of CVT-301 Compared to an Observational Control Group

NCT02352363
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
CVT-301, Observational cohort
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Scottsdale, Arizona • Fountain Valley, California • Panorama City, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes

NCT03187301
View directory record Official record
Conditions
Parkinson's Disease, Off Episodes of Parkinson Disease
Interventions
APL-130277, Placebo, Moxifloxacin
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
10
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)

NCT04542499
View directory record Official record
Conditions
Parkinson Disease
Interventions
Tavapadon, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years to 80 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
54
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 24, 2026, 5:34 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients

NCT02453386
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
tozadenant, placebo
Drug
Lead sponsor
Biotie Therapies Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
449 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
40
States / cities
Birmingham, Alabama • Sun City, Arizona • Loma Linda, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations

NCT04191577
View directory record Official record
Conditions
Parkinson Disease
Interventions
CVN424 Low Dose, CVN424 High Dose, Placebo
Drug
Lead sponsor
Cerevance Beta, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
21
States / cities
Long Beach, California • Pasadena, California • Boca Raton, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Sep 24, 2026, 5:34 AM EDT
Terminated Phase 2 Interventional Results available

A Study of E2007 In Patients With Parkinson's Disease

NCT00427011
View directory record Official record
Conditions
Parkinson's Disease
Interventions
E2007
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Peoria, Arizona • Little Rock, Arkansas • Oxnard, California + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease

NCT02224664
View directory record Official record
Conditions
Parkinson's Disease
Interventions
PF-06649751
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
Fountain Valley, California • Long Beach, California • Englewood, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 1Phase 2 Interventional

An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects

NCT00914602
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Sinemet 25-100 Oral Tablet, XP21279, Carbidopa Pill
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Peoria, Arizona • Bingham Farms, Michigan
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 24, 2026, 5:34 AM EDT